Literature DB >> 2867199

Does an endogenous methylpyridinium analogue cause Parkinson's disease?

B Testa, R Naylor, B Costall, P Jenner, C D Marsden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2867199     DOI： 10.1111/j.2042-7158.1985.tb05116.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN： 0022-3573            Impact factor:   3.765


× No keyword cloud information.
  3 in total

1.  Oxidative polymorphism of debrisoquine in Parkinson's disease.

Authors:  J Benitez; J M Ladero; F J Jimenez-Jimenez; C Martinez; A M Puerto; M J Valdivielso; A Llerena; J Cobaleda; J J Muñoz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

Review 2.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine.

Authors:  R Albores; E J Neafsey; G Drucker; J Z Fields; M A Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.